Lateral Flow Immunochromatographic Assay for Detection of Antibodies Against a Recombinant Human Adenovirus Type 3 Hexon Fragment Using Gold Nanoparticles and Quantum Dots

Kanatbek Mukantayev, Kanat Tursunov, Laura Tokhtarova, Bisultan Abirbekov

Diagnostics, 2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3390/diagnostics16162670
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background/Objectives: Human adenoviruses (HAdVs) are widely used as vectors for vaccines and gene therapy; however, pre-existing immunity can reduce their efficacy. Therefore, rapid and accessible serological methods are required to assess antibody levels against adenoviruses. Lateral flow immunochromatographic assay (LFIA) sensitivity depends on the label and antigen. In this study, we aimed to develop and evaluate LFIA systems based on gold nanoparticles (GNPs) and quantum dots (QDs) using a recombinant HAdV hexon protein. Methods: A recombinant HAdV hexon protein fragment (rhHAdV, 35 kDa; amino acids A120–R316) was expressed in Escherichia coli and purified using Ni2+ affinity chromatography. Protein identity was confirmed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, western blotting, and liquid chromatography–tandem mass spectrometry analyses. Two LFIA formats were developed using Protein G-conjugated GNPs (GNP-G) and QDs (QD-G). Analytical sensitivity was evaluated using serial dilutions of positive serum samples. Diagnostic performance was assessed using 90 human serum samples and compared with that of a commercial enzyme-linked immunosorbent assay (ELISA). Results: The rhHAdV antigen demonstrated high immunoreactivity in ELISA. Antibody detection was achieved at serum dilutions of up to 1:300 and 1:1000 for the GNP- and QD-based LFIA, respectively. Both LFIA formats showed high specificity (98.2%). Sensitivity was 96.9% and 100% for GNP-G and QD-G, respectively; ROC analysis demonstrated excellent diagnostic accuracy, with AUC values of 0.976 and 0.991, respectively. Conclusions: The findings of this study highlight the potential of QD-based LFIA as an advanced tool for rapid serodiagnostics and large-scale immunological monitoring.